Evaluating Pharmaceuticals for Health Policy and ReimbursementISBN: 978-0-7279-1784-3
Paperback
280 pages
September 2004, BMJ Books
|
“The challenge in all settings is to make the difficult
decisions in a way that is defensible, justifiable, ethical, and
equitable”
So write Nick Freemantle and Suzanne Hill in their introduction
to this important discussion on decision making in the
reimbursement of pharmaceuticals. Based around a programme
supported by the World Health Organization, chapters by leading
academics involved in the research tackle such major issues as
international pharmaceutical policy, tensions in licensing
policies, priority setting, and relationships between the
stakeholders.
Chapters include
- Development of marketing authorisation procedures for pharmaceuticals
- Interpreting clinical evidence
- International pharmaceutical policy: health creation or wealth creation?
- Development of fourth hurdle policies around the world
- Economic modelling in drug reimbursement
- Priority setting in health care: matching decision criteria with policy objectives
- Tensions in licensing and reimbursement decisions: case of riluzole for amytrophic lateral sclerosis
- Relationship between stakeholders: managing the war of words
- Medicine and the media: good information or misleading hype?
- How to promote quality use of cost-effective medicines
- Using economic evaluation to inform health policy and reimbursement: making it happen and making it sustainable
- Pricing of pharmaceuticals
- Evaluating pharmaceuticals for health policy in low and middle income country settings.
Besides the controversial issues there is a wealth of practical information including economic modelling and the experiences from the WHO programme, providing readers with workable examples. This is essential reading for clinical researchers in pharmaceuticals and policy makers everywhere.